News | Leads Implantable Devices | August 05, 2019

Abbott Recalls Ellipse Implantable Cardioverter Defibrillators Due to Exposed Aluminum Wires

Exposed aluminum wires identified in Class I recall may prevent defibrillation therapy

Abbott Recalls Ellipse Implantable Cardioverter Defibrillators Due to Exposed Aluminum Wires

August 5, 2019 — Abbott is recalling the Ellipse Implantable Cardioverter Defibrillators (ICDs) because electrical failures have been identified and determined to be due to a faulty manufacturing process, causing some aluminum wires to be partially exposed. ICDs which contain aluminum wires that are not fully insulated are prone to electrical shorting of the capacitor.  The potential patient impact could be the inability to deliver high voltage therapy. There is currently no available method or procedure to determine which of these devices have this issue prior to failure.

Abbott ICDs provide pacing for slow heart rhythms and electrical shock or pacing to stop dangerously fast heart rhythms. These cardiac devices are implanted under the skin in the upper chest area with connecting insulated wires called leads that go into the heart. A patient may need an ICD if their heartbeat is too slow (bradycardia), too fast (tachycardia) or needs coordination to treat heart failure.

On June 21, 2019, Abbott hand-delivered an Urgent Medical Device Recall letter to customers. The letter directed customers to take the following actions:

  • Review the device model and serial numbers to identify the impacted patients and return the acknowledgement form to the sales representative.

Device explant and replacement are recommended. Abbott will work with customers to provide an Abbott replacement device. The recall affects all lots manufactured between April 5 and May 29 of this year; this includes model numbers CD1377-36C, CD1377-36QC, CD1411-36Q, CD2377-36QC, CD2411-36C and CD2411-36Q. 

Abbott is not aware of any related reports of this failure occurring in any affected implanted devices. Of the 108 devices recalled in the U.S., 31 have been implanted. The complaints and MDRs available have either reported that the affected devices have been replaced or are scheduled to be replaced with another ICD generator. None of the complaint or MDRs indicate that any patient harm or adverse events have occurred, and no deaths have been reported.

Healthcare professionals and consumers may report adverse reactions or quality problems they experience using these devices to MedWatch: The FDA Safety Information and Adverse Event Reporting Program either online, by regular mail or by fax to 1-800-FDA-0178. Healthcare professionals employed by facilities that are subject to FDA's user facility reporting requirements should follow the reporting procedures established by their facilities.

For more information: www.cardiovascular.abbott/us/en/hcp/resources/product/advisories.html

 

Related ICD Content

New Technology and Market Challenges Facing Implantable Cardioverter Defibrillators

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD

Use of the Interventional CRT Approach to Solve Issues With LV Lead Placement

New Approaches to EP Lead Management

VIDEO: EP Lead Extraction Strategies

Related Content

The European Heart Rhythm Association (EHRA) electrophysiology (EP) annual meeting cancelled due to coronavirus. #COVID19 #coronavirus #2019nCoV
Feature | EP Lab | March 10, 2020 | Dave Fornell, Editor
March 10, 2020 — Novel coronavirus (...
The U.S. Food and Drug Administration (FDA) cleared the Acutus Medical SuperMap, an addition to its AcQMap 3-D imaging and mapping system used to guide electrophysiology (EP) catheter ablation procedures. Adding the SuperMap mode to the AcQMap system enables users to visualize any atrial rhythm in less than three minutes. Rapidly mapping and re-mapping the whole heart chamber facilitates a new procedural workflow in EP ablation, making it practical to execute an iterative "map, ablate, re-map" approach.
News | EP Lab | March 05, 2020
March 5, 2020 — The U.S.
 ElectroSonix
News | EP Lab | December 30, 2019
December 30, 2019 — Acoustoelectric cardiac imaging, a new, noninvasive cardiac imaging technology developed at the U
Peter Weiss, M.D., explains a Stereotaxis robotically navigated cardiac ablation procedure at Banner University Medicine Heart Institute.

Peter Weiss, M.D., explains a Stereotaxis robotically navigated cardiac ablation procedure at Banner University Medicine Heart Institute.

Feature | EP Lab | December 23, 2019 | J. Peter Weiss, M.D., MSc
Robotic technology, which helps carry out repetitive tasks efficiently and precisely, has been gaining ground in...
Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins. The future of CRM device technology.

Earlier this year, Medtronic began a worldwide pivotal study evaluating its investigational Extravascular Implantable Cardioverter Defibrillator (EV ICD) system to treat dangerously fast heart rhythms. The EV ICD system is designed to deliver lifesaving defibrillation and pacing therapy via a device the same size as traditional, transvenous ICDs, but with a lead (thin wire) placed outside the heart and veins.

Feature | EP Lab | November 11, 2019 | Hrishikesh Kadam
Cardiac rhythm management (CRM) devices in use today are evolving to raise the bar beyond monitoring and managing car
A comparison between the EPstar 2F and 6F catheters from Baylis. Electrophysiology catheters. EP lab

A comparison between the EPstar 2F and 6F catheters from Baylis.

News | EP Lab | October 31, 2019
October 31, 2019 — Baylis Medical announced the first North American use of its EPstar Fixed...
New Study Shows Chronic Epilepsy Associated With Marker of Cardiac Electrical Instability
News | EP Lab | October 24, 2019
LivaNova PLC announced the publication of a new study in Neurology, which suggests that chronic epilepsy may be...
Lenox Hill Hospital Opens New Heart Rhythm Center
News | EP Lab | August 27, 2019
Lenox Hill Hospital (New York, N.Y.) has established a brand new Heart Rhythm Center dedicated to the treatment of...
Damaged Hearts Rewired With Nanotube Fibers

Researchers at Texas Heart Institute and Rice University have confirmed that flexible, conductive fibers made of carbon nanotubes can bridge damaged tissue to deliver electrical signals and keep hearts beating despite congestive heart failure or dilated cardiomyopathy or after a heart attack. Image courtesy of Texas Heart Institute.

News | EP Lab | August 15, 2019
Thin, flexible fibers made of carbon nanotubes have now proven able to bridge damaged heart tissues and deliver the...
Cardiac Device Complications Vary Widely Among Hospitals
News | EP Lab | July 31, 2019
The chances of patients experiencing complications after having a cardiac device implanted vary according to where they...
Overlay Init